Hierarchy of Comorbidity Indicators for Obstructive Sleep Apnea

To the Editor:
Epidemiologic studies of the comorbidities of obstructive sleep apnea (OSA) have produced a list of many comorbidities, some more prevalent than others. This correspondence posits that the comorbidities, with a prevalence in the OSA population that is signifi cantly higher than their prevalence in the general population are the strongest indicators of OSA, even though these may not be the most prevalent in the OSA population.
The indicator strengths of 11 OSA comorbidities are computed by forming the ratio of each one's prevalence in the OSA population to its prevalence in the general population. Each OSA comorbidity and its prevalence were selected from an Australian study. 1 This study included . 60,000 hospital patients who had been diagnosed with OSA. These patients were the ones diagnosed with OSA from . 1.5 million randomly selected hospital records in New South Wales. The results of the computations are shown in Table 1 , 2 -5 in which the comorbidities are listed in descending order of OSA indicator strength. The sources for the estimated prevalence in the United States of each comorbidity are referred to in the table.
The recent publication 1 of the data for the prevalence of each comorbidity in a very large OSA population provides a necessary ingredient for the calculations. The database from which it was computed comprises a segment of New South Wales residents selected only by the fact that they were admitted to a hospital. Medical rules in New South Wales require that all public and some private hospitals collect all inpatient hospital records data and report them monthly to the database in the Department of Health. On the other hand, the comprehensive epidemiologic studies 2 -5 for each comorbidity have been performed in the United States. The assumption is made that the broadly-based Australian statistics for the prevalence of each comorbidity in the OSA population would apply to other countries with similar life styles, such as the United States.
It is important to recognize that OSA in Australia probably is largely undiagnosed, as it is in the United States. As a result, the statistics in reference 1 may be skewed because they are representative of only the diagnosed OSA population, not the entire OSA population. Data skewing may have occurred based on the comorbidities that the Australian medical practitioners had used as possible indicators of OSA to prompt its subsequent diagnosis. Even so, the uniqueness of this database makes it the only source to date on which to base a hierarchical analysis.
The strongest indicators are at the top of Table 1 , because the prevalence of each in the OSA population is much larger than the prevalence of that comorbidity in the general population, even though they are not the most prevalent comorbidities in the OSA population. Atrial fi brillation and fl utter is clearly the strongest indicator of OSA, gout second, and congestive heart failure a close third. 
Availability of the 6-Min Walk Test in Coal Workers' Pneumoconiosis Evaluations
To the Editor:
Not only is coal workers' pneumoconiosis (CWP) still one of the most predominant occupational diseases, even now rates of CWP are increasing, based on the compensation records from the Industrial Accident Compensation Insurance that is operated by the Korea Labor Welfare Corporation. In this manner, it is important to accurately estimate malfunction-induced disorders. The current CWP diagnosis system is generally based on history, examination, radiology, and lung function tests; however, those methods are not suffi cient to confi rm or refute CWP, and, therefore, it is important to develop complementary methods. 1 We All variables were adjusted for age, sex, height, and weight when entered into the models.
recommend the 6-min walk test (6MWT) as a complementary diagnosis method for CWP. The 6MWT, developed by Balke in 1963, 2 is one of the tests widely used to assess functional exercise capacity evaluated by measuring the distance walked during 6 min. The merits of this test are that it is easy to administer and it is better tolerated and more refl ective of the activities of daily living than other walk tests. 3 -5 Most activities of daily life usually are performed at a submaximal level of exertion, so the 6MWT seems to better refl ect the functional exercise level for daily physical activities. Accordingly, the 6MWT would be a good estimation tool for objective health and assessment in CWP.
In our study, when we compared the 6-min walk distance (6MWD) to other common diagnostic inspections, such as respiratory symptoms, chest radiographs, and pulmonary function tests, we found that the 6MWD was signifi cantly related to coughs, Medical Research Council dyspnea (MRC dyspnea), FVC, maximal voluntary ventilation (MVV), and breathing reserve index (BRI) measured using minute ventilation (V · e ) divided by MVV [(V · e րMVV)100] during maximum exercise estimated by the Master two-step exercise test. Moreover, the 6MWD decreased linearly in phases for each variable (dyspnea, cough, FVC, MVV, or BRI) that was statistically signifi cant ( Table 1 ) .
The study by Villalba et al (January 2007) 3 compared the 6MWD to other clinical variables in patients with scleroderma, and the results indicated that 6MWD was associated with age, dyspnea index, fi brosis on chest radiography, FVC , 80% of predicted, pulmonary arterial systolic BP Ն 30 mm Hg, and
